I’ve noticed many comments criticising RCTs of masks or filters come from engineers
These criticisms are often, understandably, caused by misunderstandings about what RCTs are for (engineers do not usually use RCTs)
Here is my attempt to explain
https://t.co/yrhWmsfLne
🛡️ Why are transplant recipients especially vulnerable to infections as they age?
At #IDWeek2026, Anoma Nellore, MD, explored how immunosenescence + “inflammaging” compound the effects of transplantation.
Key takeaways 🧵👇
Agree, of we’re not all moving to Bluesky or Roon, we might as well ask me on here and intermittently clean our feeds to keep it all the politics/racism
#IDtwitter forever!
We have a commentary out on some really interesting findings by colleagues in UCL and Finland on some of the maths behind some of the high profile shingles -> dementia analyses. In brief +
Paper: https://t.co/unZ6RdY79S
Commentary: https://t.co/d4OfTq9m00
@ABsteward The coolest part to me though was the protocol had patients switch to PO (cephalexin, cefadroxil, or linezolid) at 48-72hr after blood culture clearance. Nice to see early PO protocolized like this, especially with cephalexin and cefadroxil. I'm sure @BradSpellberg will be a fan
@ppsantyago@ABsteward@BradSpellberg@PulmCrit@IDstewardship 1. It was very boring.
2. Didn't learn as much.
3. There was zero evidence it was "nicer."
4. Agree that curation of what you say and who you block can make this platform ok.
Had another discussion with an MD concerned re fosfomycin for pyelo because "it doesn't get into the kidney". The damage guidelines have done medicine is incalculable. Perpetetuators of myth & legend. Forcing patients to get IV when they don't need it. It is time for a reckoning.
The 1st of 2 new articles in CID critical of clinical guideline process is out. See
https://t.co/NqHCE8MhSj
It is long past time clinical guidelines incorporate the humility of uncertainty & stop creating standards of care absent of reproducible prospective studies.
@ABsteward
Underpinning this is a concept that became very apparent during #COVID19
Is the presentation missed, delayed or or late?
https://t.co/XpMWk6cNQq
When undertaking reviews of these cases understanding these subtle differences critical to ensure true learning for the future
A tour-de-force in healthcare communication from @apsmunro
The contradiction of a healthcare campaign promoting illness recognition only to see it potentially make the problem worse....
https://t.co/gvRk8TYgHm
Nice explanation from @apsmunro
Sepsis is rare, but devastating. It is a needle in a haystack for emergency care. Campaigns for ‘early awareness’ makes the haystack bigger, meaning that the needles are even more difficult to find.
Increasing awareness of sepsis simultaneously increases the number of "missed" diagnoses, whilst also increasing the number of diagnoses made early
This confusing paradox stems from the difficulties of assessing children earlier in the disease process
https://t.co/cEsvNcvSGh
There is a massive amount of attention on sepsis and "increasing awareness" among the public
There seems to be little recognition that increasing the amount of early presentations will also, paradoxically, increase the number of "missed" diagnoses
https://t.co/cEsvNcvkQJ
@surf4children I don’t think it will be an issue beyond the usual UTIs for outpatients, for which fosfo and piv are pretty good
Market is moving in this space too with eg gepotidacin
I recently gave a talk at a paediatric OPAT conference which I titled “The death of OPAT”
Given the superiority of oral antibiotics in almost all cases, prolonged courses of IV for children should be considered a failure unless there is an exceptional justification